Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study
2024

Short-Course Blinatumomab for B-Cell Leukemia

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): Yin Jin, Cai Xiaoya, Qian Bingxin, Liu Ying, Li Dengju

Primary Institution: Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology

Hypothesis

Can short-course blinatumomab treatment effectively bridge patients with relapsed/refractory B-cell acute lymphoblastic leukemia to further salvage therapy?

Conclusion

Short-course blinatumomab treatment can provide significant clinical benefits and is a viable alternative for cost-efficient management of relapsed/refractory B-cell acute lymphoblastic leukemia.

Supporting Evidence

  • 83.3% of patients achieved morphological complete remission.
  • 40% of patients were minimal residual disease-negative.
  • Estimated 2-year overall survival rate was 82.62%.
  • Estimated 2-year progression-free survival rate was 78.35%.
  • Patients receiving further treatment had significantly better outcomes.

Takeaway

This study shows that a shorter treatment with blinatumomab can help patients with a type of blood cancer feel better and get ready for more treatments without spending too much money.

Methodology

Retrospective analysis of clinical data from 30 patients treated with short-course blinatumomab between 2021 and 2022.

Limitations

The study had a limited number of patients and was retrospective in nature.

Participant Demographics

Median age was 38 years, with 14 men and 16 women.

Statistical Information

P-Value

p<0.0001

Confidence Interval

95%CI 63.14–92.37 for OS, 95%CI 57.79–89.71 for PFS

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1002/cam4.70515

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication